Browsing by Author Catalano, Alberto

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2012All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Bradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Catalano, Alberto; Collins, Marnie; Dilulio, J.; et al, various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Tiley, Campbell; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineAll-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol.120, 8, 2012,pp 1570-1580
2005Molecular biology of lymphoma in the microarray era.Iland, Harry; Catalano, Alberto; Central Clinical School: MedicineMolecular biology of lymphoma in the microarray era., Pathology 2005, vol.37,(6),2005,pp 508-522
2007The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemiaIland, Harry; Campbell, Lynda J.; Catalano, Alberto; Dawson, Mark A.; Opat, Stephen; Schwarer, Anthony; Somana, Karthiga; Central Clinical School: MedicineThe PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia, Blood, vol.110,(12),2007,pp 4073-4076
2012Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Allen, John; Al-Shabeeb, Ammira; Ho, Phoebe (Joy); Iland, Harry; Joshua, Douglas; Lau, Edwin; Ling, Silvia; Nikolic, Angela; Catalano, Alberto; Fleming, Shaun; Harrison, Simon James; Horvath, N; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Melanoma FoundationResponse of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1, Haematologica: the hematology journal, vol.97, 1, 2012,pp 64-72
2015Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialBradstock, Kenneth; Hertzberg, Mark; Iland, Harry; Browett, Peter; Campbell, Lynda J.; Catalano, Alberto; Collins, Marnie; Di Iulio, Juliana L.; et al, Various; Firkin, Frank; Grigg, Andrew P.; Hugman, Amanda; Reynolds, John; Supple, Shane; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Central Clinical School: MedicineUse of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, The Lancet Haematology, vol.2, 9, 2015,pp e357-e366